Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Ischemix logo — company profile

Ischemix

Founded 1999 United States Maynard, United States 6 employees Venture round Total: $6.60M

General Information

Company Name Ischemix
Founded Year 1999
Location United States Maynard, United States
Employees 6
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Ischemix. To contact Ischemix, visit ischemix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ischemix compare?

A PDF of Ischemix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ischemix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ischemix

Ischemix is a privately-held pharmaceutical company that has developed novel cytoprotective compounds for the prevention and treatment of serious conditions of the kidney, heart, and other organ systems. Founded in 1999 in the United States, the company received a significant $6.60M Venture Round investment on June 5, 2014. Ischemix's focus on developing innovative solutions for critical medical needs positions it as an intriguing prospect for venture capital investors seeking opportunities in the pharmaceutical and biotech industries. With its cutting-edge approach to cytoprotection, Ischemix has the potential to make a meaningful impact on the treatment and prevention of severe organ system conditions, making it an attractive option for investors looking to tap into the healthcare innovation space.

Business keywords: pharmaceutical, cytoprotective compounds, kidney, heart, organ systems, drug development, medical research, biopharmaceuticals

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $6.60M -
05 Jun 2014

Ischemix Alternatives & Competitors

View All Alternatives
Ischemix vs
THRASOS LIMITED
THRASOS LIMITED

Pioneering targeted therapies to prevent and treat severe organ failure, with a focus on kidney dise...

Series D
2 employees
Biotechnology, Health Care
Ischemix vs
Lakewood-Amedex Inc.
Lakewood-Amedex Inc. United States

Improving lives by fighting challenging infections through groundbreaking innovation.

Venture round
10 employees
Biopharma, Biotechnology
Ischemix vs
Atorvia Health Technologies
Atorvia Health Technologies Canada

Fearlessly tackling kidney failure

Grant
5 employees
Biotechnology, Health Care
View all alternatives

FAQ About Ischemix

Ischemix is a privately-held pharmaceutical company that has developed novel cytoprotective compounds for the prevention and treatment of serious conditions of the kidney, heart and other organ systems.
Ischemix was founded in 1999.
Ischemix is headquartered in Maynard, United States.
Ischemix has approximately 6 employees.
Ischemix has completed 1 funding round, raising a total of $6.60M. The latest funding stage is Venture round.
Top alternatives and competitors to Ischemix include THRASOS LIMITED, Lakewood-Amedex Inc., Atorvia Health Technologies, NephRx Corporation, Pregenerate Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ischemix and THRASOS LIMITED are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ischemix, https://bouncewatch.com/company/ischemix, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes